BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 23, 2007
 |  BioCentury  |  Product Development

A double-whammy

After reporting setbacks for its two most advanced programs last week, Metabasis Therapeutics Inc. is left with a heap of data to sort through and the possibility that it may find its metabolic diseases program bumped back to Phase I.

The company announced that both doses of lead compound CS-917 missed the primary endpoint of reduction from baseline in HbA1c in a Phase IIb trial to treat Type II diabetes, and that Schering-Plough Corp. is returning rights to pradefovir, which had completed Phase II testing for HBV.

If there turns out to be a problem with CS-917's mechanism of action - which MBRX does not think will be the case - the company's MB07803 second-generation molecule could be at risk, too. That would leave MB07811, in Phase Ib testing to treat hyperlipidemia, as its lead metabolic program.

In its liver diseases program, of which pradefovir is a part, MB07133 is next in line. It has completed a Phase I/II...

Read the full 812 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >